{"id":"W3013209996","doi":"10.1016/j.jchf.2020.03.002","title":"Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction","year":2020,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"National Center for Advancing Translational Sciences; National Heart, Lung, and Blood Institute; National Medical Research Council; Baxter Healthcare Corporation; National Institutes of Health; Vifor Pharma; Daiichi-Sankyo; Kidney Research UK; Bayer Fund; Actavis; Boston Scientific Corporation; KU Leuven; Takeda Pharmaceuticals U.S.A.; Sanofi Pasteur; United Therapeutics Corporation; Cytokinetics; AbbVie; Novo Nordisk; MyoKardia; Servier; Bayer; Gilead Sciences; Medtronic; Sanofi; Roche; Novartis; Merck; GlaxoSmithKline; Akebia Therapeutics; Bristol-Myers Squibb; AstraZeneca; Actelion Pharmaceuticals; Pfizer; Boehringer Ingelheim; Amgen; American Heart Association; Abbott Laboratories","keywords":"Medicine; Heart failure; Sacubitril; Sacubitril, Valsartan; Natriuretic peptide; Ejection fraction; Valsartan; Internal medicine; Cardiology; Heart failure with preserved ejection fraction; Blood pressure","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002497915,0.0004021136,0.001000086,0.0003102438,0.00009337756,0.00004032121,0.00009889565,0.000251993,0.0002036853],"category_scores_gemma":[0.0002600609,0.0003216084,0.0001756368,0.0009616868,0.00006884828,0.0002802635,0.00005280931,0.0006315476,0.0002351958],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001778086,"about_ca_system_score_gemma":0.0001826495,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001478121,"about_ca_topic_score_gemma":0.0001799401,"domain_scores_codex":[0.9974455,0.0002102065,0.0004862236,0.0006638591,0.0006955254,0.000498668],"domain_scores_gemma":[0.9987732,0.0001918682,0.0001362438,0.0004022293,0.0001740033,0.0003224264],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.006558434,0.002253417,0.4119729,0.0045339,0.0004504907,0.0008206211,0.0008753614,0.0002084598,0.1502251,0.0002051915,0.4213322,0.0005639375],"study_design_scores_gemma":[0.01219585,0.01327494,0.1643328,0.002133513,0.0007555095,0.0001641273,0.0008726807,0.0007817818,0.1136535,0.00004642017,0.6909848,0.0008040883],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.934546,0.0001372696,0.00009680161,0.06139801,0.000121638,0.003232496,0.000004095141,0.00019759,0.0002660866],"genre_scores_gemma":[0.9881784,0.00001272205,0.009289364,0.001495834,0.0003461816,0.0001394717,0.00004813866,0.00006514085,0.0004247499],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2696526,"threshold_uncertainty_score":0.9999236,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01475409723559611,"score_gpt":0.2656894741211548,"score_spread":0.2509353768855587,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}